Combined Immunodeficiencies

immunoloji-17-1-2024

Mehmet KILINÇa
aNecmettin Erbakan University Faculty of Medicine, Department of Internal Medicine, Division of Immunology and Allergy Diseases, Konya, Türkiye

Kılınç M. Combined immunodeficiencies. Çölkesen F, ed. Primary Immunodeficiency Diseases in Adults. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.45-50.

ABSTRACT
Inborn errors of immunity, also called as primary immunodeficiencies (PIDs), are a group of congenital and heterogeneous diseases affecting the immune system. Combined immunodeficiencies (CIDs) constitute a subgroup of PIDs characterized by T-cell dysfunction, and typically present with recurrent infections, inflammation, autoimmunity, malignancy, and allergic manifestations. Based on their pathophysiology, CIDs are grouped into different classes, namely T cell development defects, T cell receptor signaling defects, cytokine signaling defects, cytoskeleton adhesion, migration and organization defects, apoptosis, DNA repair, and metabolic pathways. In addition to recurrent bacterial infections, invasions by opportunistic pathogens such as mycobacteria and fungi can also be observed. Early diagnosis, even before clinical symptoms appear, is possible with newborn screening. This also allows for a better management, thereby improving the prognosis. In this review diagnosis, treatment, and clinical management of CIDs are discussed and detailed.

Keywords: Primary immunodeficiency; combined immunodeficiencies; inborn errors of immunity; monogenic defects

Referanslar

  1. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-38. Erratum in: JAMA. 2014;312(20):2169. Bonagura, Vincent R [Added].
  2. Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, Cunningham-Rundles C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol. 2020;40(1):66-81. [Crossref]  [PubMed]  [PMC]
  3. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al; Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e1-78.
  4. Bustamante Ogando JC, Partida Gaytán A, Aldave Becerra JC, Álvarez Cardona A, Bezrodnik L, Borzutzky A, et al. Latin American consensus on the supportive management of patients with severe combined immunodeficiency. J Allergy Clin Immunol. 2019;144(4):897-905. [Crossref]  [PubMed]
  5. Condino-Neto A, Franco JL, Espinosa-Rosales FJ, Leiva LE, King A, Porras O, et al. Advancing the management of primary immunodeficiency diseases in Latin America: Latin American Society for Immunodeficiencies (LASID) Initiatives. Allergol Immunopathol (Madr). 2012;40(3):187-93. [Crossref]  [PubMed]
  6. Giardino G, Borzacchiello C, De Luca M, Romano R, Prencipe R, Cirillo E, et al. T-Cell Immunodeficiencies With Congenital Alterations of Thymic Development: Genes Implicated and Differential Immunological and Clinical Features. Front Immunol. 2020;11:1837. [Crossref]  [PubMed]  [PMC]
  7. Rota IA, Dhalla F. FOXN1 deficient nude severe combined immunodeficiency. Orphanet J Rare Dis. 2017;12(1):6. [Crossref]  [PubMed]  [PMC]
  8. Fayez EA, Qazvini FF, Mahmoudi SM, Khoei S, Vesaltalab M, Teimourian S. Diagnosis of radiosensitive severe combined immunodeficiency disease (RS-SCID) by Comet Assay, management of bone marrow transplantation. Immunobiology. 2020;225(3):151961. [Crossref]  [PubMed]
  9. Dadi HK, Simon AJ, Roifman CM. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med. 2003;349(19):1821-8. Erratum in: N Engl J Med. 2004;350(17):1803. [Crossref]  [PubMed]
  10. Sharifinejad N, Jamee M, Zaki-Dizaji M, Lo B, Shaghaghi M, Mohammadi H, et al. Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review. Front Immunol. 2020;11:831. [Crossref]  [PubMed]  [PMC]
  11. Abolhassani H, Edwards ES, Ikinciogullari A, Jing H, Borte S, Buggert M, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. 2017;214(1):91-106. [Crossref]  [PubMed]  [PMC]
  12. Olbrich P, Freeman AF. STAT1 and STAT3 mutations: important lessons for clinical immunologists. Expert Rev Clin Immunol. 2018;14(12):1029-41. [Crossref]  [PubMed]
  13. Ramaekers FC, Bosman FT. The cytoskeleton and disease. J Pathol. 2004;204(4):351-4. [Crossref]  [PubMed]
  14. Bartels AK, Banks TA, Bay JL. Pearls and pitfalls: Autoimmune lymphoproliferative syndrome and autoimmune lymphoproliferative syndrome-like disease. Allergy & Asthma Proceedings; 2017. [Crossref]  [PubMed]
  15. Amirifar P, Ranjouri MR, Yazdani R, Abolhassani H, Aghamohammadi A. Ataxia-telangiectasia: A review of clinical features and molecular pathology. Pediatr Allergy Immunol. 2019;30(3):277-88. [Crossref]  [PubMed]
  16. Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations. J Clin Immunol. 2017;37(7):626-37. [Crossref]  [PubMed]
  17. Hawley TS, Hawley R. Flow cytometry protocols: Springer Science & Business Media; 2008.
  18. Cirillo E, Giardino G, Gallo V, D'Assante R, Grasso F, Romano R, et al. Severe combined immunodeficiency--an update. Ann N Y Acad Sci. 2015;1356:90-106. [Crossref]  [PubMed]
  19. Moraes-Pinto MI, Ono E, Santos-Valente EC, Almeida LC, Andrade PR, Dinelli MI, et al. Lymphocyte subsets in human immunodeficiency virus-unexposed Brazilian individuals from birth to adulthood. Mem Inst Oswaldo Cruz. 2014;109(8):989-98. [Crossref]  [PubMed]  [PMC]
  20. Farmer JR, Mahajan VS. Molecular Diagnosis of Inherited Immune Disorders. Clin Lab Med. 2019;39(4):685-97. [Crossref]  [PubMed]
  21. Comrie WA, Lenardo MJ. Molecular Classification of Primary Immunodeficiencies of T Lymphocytes. Adv Immunol. 2018;138:99-193. [Crossref]  [PubMed]  [PMC]
  22. Somech R, Etzioni A. A call to include severe combined immunodeficiency in newborn screening program. Rambam Maimonides Med J. 2014;5(1):e0001. [Crossref]  [PubMed]  [PMC]
  23. King J, Ludvigsson JF, Hammarström L. Newborn screening for primary immunodeficiency diseases: the past, the present and the future. International Journal of Neonatal Screening. 2017;3(3):19. [Crossref]
  24. Aranda CS, Guimarães RR, de Gouveia-Pereira Pimentel M. Combined immunodeficiencies. J Pediatr (Rio J). 2021;97 Suppl 1(Suppl 1):S39-S48. [Crossref]  [PubMed]  [PMC]
  25. He YY, Liu B, Xiao XP. [Hyper-IgE syndromes]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;31(11):892-6. Chinese.
  26. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Arch Dis Child. 2006;91(7):610-1. [Crossref]  [PubMed]  [PMC]
  27. Karalis A, Tischkowitz M, Millington GW. Dermatological manifestations of inherited cancer syndromes in children. Br J Dermatol. 2011;164(2):245-56. [Crossref]  [PubMed]
  28. Eberting CL, Davis J, Puck JM, Holland SM, Turner ML. Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol. 2004;140(9):1119-25. [Crossref]  [PubMed]
  29. Santana PRP, Medeiros AK, Barbisan CC, Gomes ACP, Marchiori E. Hyperimmunoglobulin E syndrome (Job syndrome): chest CT findings. J Bras Pneumol. 2018;44(4):335-6. [Crossref]  [PubMed]  [PMC]
  30. Crawford TO. Ataxia telangiectasia. Semin Pediatr Neurol. 1998;5(4):287-94. [Crossref]  [PubMed]
  31. Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser. 1985;19:1-63.
  32. Lewis RF, Lederman HM, Crawford TO. Ocular motor abnormalities in ataxia telangiectasia. Ann Neurol. 1999;46(3):287-95. [Crossref]  [PubMed]
  33. Lin DD, Barker PB, Lederman HM, Crawford TO. Cerebral abnormalities in adults with ataxia-telangiectasia. AJNR Am J Neuroradiol. 2014;35(1):119-23. [Crossref]  [PubMed]  [PMC]
  34. Kraus M, Lev A, Simon AJ, Levran I, Nissenkorn A, Levi YB, et al. Disturbed B and T cell homeostasis and neogenesis in patients with ataxia telangiectasia. J Clin Immunol. 2014;34(5):561-72. [Crossref]  [PubMed]
  35. Reiman A, Srinivasan V, Barone G, Last JI, Wootton LL, Davies EG, et al. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer. 2011;105(4):586-91. [Crossref]  [PubMed]  [PMC]
  36. Kaneko H, Fukao T, Kondo N. The function of RecQ helicase gene family (especially BLM) in DNA recombination and joining. Adv Biophys. 2004;38:45-64. [Crossref]
  37. Kondo N. [Bloom syndrome]. Nihon Rinsho. 2000;58(7):1460-6. Japanese.
  38. Dominguez M, Crushell E, Ilmarinen T, McGovern E, Collins S, Chang B, Fleming P, Irvine AD, Brosnahan D, Ulmanen I, Murphy N, Costigan C. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in the Irish population. J Pediatr Endocrinol Metab. 2006;19(11):1343-52. [Crossref]  [PubMed]
  39. Seif AE. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet. 2011;204(5):227-44. [Crossref]  [PubMed]
  40. Condino-Neto A, Costa-Carvalho BT, Grumach AS, King A, Bezrodnik L, Oleastro M, et al. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Allergol Immunopathol (Madr). 2014;42(3):245-60. [Crossref]  [PubMed]
  41. Papadopoulou-Alataki E, Hassan A, Davies EG. Prevention of infection in children and adolescents with primary immunodeficiency disorders. Asian Pac J Allergy Immunol. 2012;30(4):249-58.
  42. Barkai G, Somech R, Stauber T, Barziali A, Greenberger S. Bacille Calmette-Guerin (BCG) complications in children with severe combined immunodeficiency (SCID). Infect Dis (Lond). 2019;51(8):585-92. [Crossref]  [PubMed]
  43. Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J. 2012;12(3):228-43.
  44. Notarangelo LD, Forino C, Mazzolari E. Stem cell transplantation in primary immunodeficiencies. Curr Opin Allergy Clin Immunol. 2006;6(6):443-8. [Crossref]  [PubMed]
  45. Gonçalves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017;15(3):369-75. [Crossref]  [PubMed]  [PMC]